{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:11:15Z","timestamp":1789128675526,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006096","name":"Shiraz Transplant Research Center, Shiraz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Genetic abnormalities might have important role in pathogenesis of hepatic steatosis after liver transplantation. We aimed to investigate association between genetic variations in transmembrane 6 superfamily member 2 (<jats:italic>TM6SF2)<\/jats:italic> rs58542926, proprotein convertase subtilisin\/kexin type 9 (<jats:italic>PCSK9)<\/jats:italic> rs505151 and proprotein convertase subtilisin\/kexin type 7 (<jats:italic>PCSK7<\/jats:italic>) rs2277287 with hepatic steatosis in liver transplant recipients.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a cross-sectional study, adult (&gt;\u200918\u00a0years) liver transplant recipients who were referred for their routine post-transplant follow-up between June 2018 and September 2018 were included in the study. Hepatic steatosis in transplant recipients was assessed by controlled attenuation parameter (CAP). Polymerase chain reaction-restriction fragment length polymorphism (PCR\u2013RFLP) was used to study <jats:italic>TM6SF2<\/jats:italic> rs58542926, <jats:italic>PCSK7<\/jats:italic> rs2277287 and <jats:italic>PCSK9<\/jats:italic> rs505151 genotypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>107 liver transplant recipients were included. There was no association between different genotypes of <jats:italic>PCSK9<\/jats:italic> rs505151 and <jats:italic>PCSK7<\/jats:italic> rs2277287 with hepatic steatosis in liver transplant recipients (<jats:italic>P<\/jats:italic> value\u2009&gt;\u20090.05). The presence of TT genotype of <jats:italic>TM6SF2<\/jats:italic> rs58542926 was higher in patients with hepatic steatosis measured by CAP after liver transplantation. In patients with moderate and severe hepatic steatosis (grade 2 and 3 steatosis), AG\u2009+\u2009GG genotypes of PCSK9 rs505151 were more prevalent than AA genotype (OR 8.667; 95% CI 1.841\u201340.879; <jats:italic>P<\/jats:italic> value\u2009=\u20090.004) compared to patients with mild steatosis (grade 1). In multivariate regression model, AG\u2009+\u2009GG genotypes of <jats:italic>PCSK9<\/jats:italic> rs505151 were associated with moderate and severe steatosis in liver transplant recipients (OR 5.747; 95% CI 1.086\u201330.303; <jats:italic>P<\/jats:italic> value\u2009=\u20090.040).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Genetic variations in <jats:italic>TM6SF2<\/jats:italic> rs58542926 and <jats:italic>PCSK9<\/jats:italic> rs505151 might be associated with hepatic steatosis in liver transplant recipients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-02041-8","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T11:02:33Z","timestamp":1638874953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study"],"prefix":"10.1186","volume":"21","author":[{"given":"Ahad","family":"Eshraghian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Moasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Azarpira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Fattahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Nikeghbalian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ali","family":"Malek-Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Geramizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"issue":"10","key":"2041_CR1","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/lt.25320","volume":"24","author":"AS Bodzin","year":"2018","unstructured":"Bodzin AS, Baker TB. Liver transplantation today: where we are now and where we are going. Liver Transpl. 2018;24(10):1470\u20135. https:\/\/doi.org\/10.1002\/lt.25320.","journal-title":"Liver Transpl"},{"issue":"6","key":"2041_CR2","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/hep.23595","volume":"51","author":"TE Starzl","year":"2010","unstructured":"Starzl TE, Fung JJ. Themes of liver transplantation. Hepatology. 2010;51(6):1869\u201384. https:\/\/doi.org\/10.1002\/hep.23595.","journal-title":"Hepatology"},{"issue":"4","key":"2041_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.hpb.2019.07.015","volume":"22","author":"A Eshraghian","year":"2020","unstructured":"Eshraghian A, Nikeghbalian S, Kazemi K, Shamsaeefar A, Geramizadeh B, Malek-Hosseini SA. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB (Oxford). 2020;22(4):521\u20138. https:\/\/doi.org\/10.1016\/j.hpb.2019.07.015.","journal-title":"HPB (Oxford)"},{"key":"2041_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ajg.2009.717","volume":"105","author":"J Dumortier","year":"2010","unstructured":"Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of \u201cseed and soil.\u201d Am J Gastroenterol. 2010;105:613\u201320.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2041_CR5","doi-asserted-by":"publisher","first-page":"12701","DOI":"10.1038\/s41598-020-69571-1","volume":"10","author":"A Eshraghian","year":"2020","unstructured":"Eshraghian A, Nikeghbalian S, Shamsaeefar A, Kazemi K, Fattahi MR, Malek-Hosseini SA. Hepatic steatosis and liver fat contents in liver transplant recipients are associated with serum adipokines and insulin resistance. Sci Rep. 2020;10(1):12701. https:\/\/doi.org\/10.1038\/s41598-020-69571-1.","journal-title":"Sci Rep"},{"issue":"2","key":"2041_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1055\/s-0039-1679920","volume":"39","author":"S Sookoian","year":"2019","unstructured":"Sookoian S, Pirola CJ. Genetics of nonalcoholic fatty liver disease: from pathogenesis to therapeutics. Semin Liver Dis. 2019;39(2):124\u201340. https:\/\/doi.org\/10.1055\/s-0039-1679920.","journal-title":"Semin Liver Dis"},{"key":"2041_CR7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461\u20135.","journal-title":"Nat Genet"},{"key":"2041_CR8","doi-asserted-by":"publisher","first-page":"1567\u20131576. 1576","DOI":"10.1053\/j.gastro.2010.07.057","volume":"139","author":"N Chalasani","year":"2010","unstructured":"Chalasani N, Guo X, Loomba R, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology. 2010;139:1567\u20131576. 1576.e1\u20136.","journal-title":"Gastroenterology"},{"issue":"12","key":"2041_CR9","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.cgh.2013.06.025","volume":"11","author":"A Finkenstedt","year":"2013","unstructured":"Finkenstedt A, Auer C, Glodny B, et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol. 2013;11(12):1667\u201372. https:\/\/doi.org\/10.1016\/j.cgh.2013.06.025.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2041_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352\u20136.","journal-title":"Nat Genet"},{"issue":"2","key":"2041_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/hep.27556","volume":"61","author":"S Sookoian","year":"2015","unstructured":"Sookoian S, Casta\u00f1o GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology. 2015;61(2):515\u201325. https:\/\/doi.org\/10.1002\/hep.27556.","journal-title":"Hepatology"},{"issue":"6","key":"2041_CR12","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1194\/jlr.M075028","volume":"58","author":"G Musso","year":"2017","unstructured":"Musso G, Cipolla U, Cassader M, et al. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. J Lipid Res. 2017;58(6):1221\u20139. https:\/\/doi.org\/10.1194\/jlr.M075028.","journal-title":"J Lipid Res"},{"issue":"2","key":"2041_CR13","doi-asserted-by":"publisher","first-page":"E345","DOI":"10.1210\/jc.2014-3340","volume":"100","author":"CW Tsai","year":"2015","unstructured":"Tsai CW, North KE, Tin A, et al. Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians. J Clin Endocrinol Metab. 2015;100(2):E345\u20139. https:\/\/doi.org\/10.1210\/jc.2014-3340.","journal-title":"J Clin Endocrinol Metab"},{"key":"2041_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clinbiochem.2020.01.003","volume":"77","author":"M Paquette","year":"2020","unstructured":"Paquette M, Gauthier D, Chamberland A, et al. Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. Clin Biochem. 2020;77:20\u20135.","journal-title":"Clin Biochem"},{"issue":"2","key":"2041_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/liv.14711","volume":"41","author":"S Grimaudo","year":"2021","unstructured":"Grimaudo S, Bartesaghi S, Rametta R, et al. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. Liver Int. 2021;41(2):321\u201332.","journal-title":"Liver Int"},{"key":"2041_CR16","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1073\/pnas.93.8.3388","volume":"93","author":"NG Seidah","year":"1996","unstructured":"Seidah NG, Hamelin J, Mamarbachi M, et al. CDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc Natl Acad Sci U S A. 1996;93:3388\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2041_CR17","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825\u201335.","journal-title":"Ultrasound Med Biol"},{"key":"2041_CR18","first-page":"3998","volume":"63","author":"TC Lorenz","year":"2012","unstructured":"Lorenz TC. Polymerase chain reaction: basic protocol plus troubleshooting and optimization strategies. J Vis Exp. 2012;63:3998.","journal-title":"J Vis Exp"},{"issue":"5","key":"2041_CR19","first-page":"351","volume":"17","author":"E Moasser","year":"2014","unstructured":"Moasser E, Azarpira N, Shirazi B, Saadat M, Geramizadeh B. Genetic polymorphisms of glutathione-s-transferase M1 and T1 genes with risk of diabetic retinopathy in Iranian population. Iran J Basic Med Sci. 2014;17(5):351\u20136.","journal-title":"Iran J Basic Med Sci"},{"issue":"5","key":"2041_CR20","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1038\/ncomms5309","volume":"30","author":"YL Liu","year":"2014","unstructured":"Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;30(5):4309. https:\/\/doi.org\/10.1038\/ncomms5309.","journal-title":"Nat Commun"},{"issue":"6","key":"2041_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/jgh.14056","volume":"33","author":"BK Koo","year":"2018","unstructured":"Koo BK, Joo SK, Kim D, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2018;33(6):1277\u201385. https:\/\/doi.org\/10.1111\/jgh.14056.","journal-title":"J Gastroenterol Hepatol"},{"key":"2041_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng.2926","volume":"46","author":"OL Holmen","year":"2014","unstructured":"Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet. 2014;46:345\u201351.","journal-title":"Nat Genet"},{"key":"2041_CR23","doi-asserted-by":"publisher","first-page":"8913","DOI":"10.1073\/pnas.1323785111","volume":"111","author":"H Mahdessian","year":"2014","unstructured":"Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A. 2014;111:8913\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2041_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/TP.0000000000002876","volume":"104","author":"I M\u00edkov\u00e1","year":"2020","unstructured":"M\u00edkov\u00e1 I, Ne\u0159oldov\u00e1 M, Hub\u00e1\u010dek JA, et al. Donor PNPLA3 and TM6SF2 variant alleles confer additive risks for graft steatosis after liver transplantation. Transplantation. 2020;104(3):526\u201334. https:\/\/doi.org\/10.1097\/TP.0000000000002876.","journal-title":"Transplantation"},{"issue":"34","key":"2041_CR25","doi-asserted-by":"publisher","first-page":"10054","DOI":"10.3748\/wjg.v21.i34.10054","volume":"21","author":"ZT Liu","year":"2015","unstructured":"Liu ZT, Chen TC, Lu XX, et al. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients. World J Gastroenterol. 2015;21(34):10054\u20136. https:\/\/doi.org\/10.3748\/wjg.v21.i34.10054.","journal-title":"World J Gastroenterol"},{"key":"2041_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ajhg.2014.01.009","volume":"94","author":"GM Peloso","year":"2014","unstructured":"Peloso GM, Auer PL, Bis JC, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet. 2014;94:223\u201332.","journal-title":"Am J Hum Genet"},{"key":"2041_CR27","doi-asserted-by":"publisher","first-page":"427433","DOI":"10.1038\/jhg.2015.170","volume":"61","author":"M Kurano","year":"2016","unstructured":"Kurano M, Tsukamoto K, Kamitsuji S, et al. Genome-wide association study of serum lipids confirms previously reported associations as well as new associations of common SNPs within PCSK7 gene with triglyceride. J Hum Genet. 2016;61:427433.","journal-title":"J Hum Genet"},{"issue":"3","key":"2041_CR28","first-page":"4986","volume":"10","author":"QH Zhang","year":"2017","unstructured":"Zhang QH, Yin RX, et al. Association of the PCSK7 rs2277287 polymorphismand serum lipid levels in the Jing and Han populations. Int J Clin Exp Med. 2017;10(3):4986\u20135000.","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"2041_CR29","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1194\/jlr.P090449","volume":"60","author":"P Dongiovanni","year":"2019","unstructured":"Dongiovanni P, Meroni M, Baselli G, et al. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. J Lipid Res. 2019;60(6):1144\u201353. https:\/\/doi.org\/10.1194\/jlr.P090449.","journal-title":"J Lipid Res"},{"key":"2041_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.metabol.2017.07.006","volume":"76","author":"Y Gong","year":"2017","unstructured":"Gong Y, Ma Y, Ye Z, et al. Thyroid stimulating hormone exhibits the impact on LDLR\/LDL-c via up-regulating hepatic PCSK9 expression. Metabolism. 2017;76:32\u201341. https:\/\/doi.org\/10.1016\/j.metabol.2017.07.006.","journal-title":"Metabolism"},{"key":"2041_CR31","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jacc.2005.01.051","volume":"45","author":"SN Chen","year":"2005","unstructured":"Chen SN, Ballantyne CM, Gotto AM Jr, Tan Y, Willerson JT, Marian AJ. A common pcsk9 haplotype, encompassing the e670g coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005;45:1611\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2041_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12944-017-0506-6","volume":"16","author":"C Qiu","year":"2017","unstructured":"Qiu C, Zeng P, Li X, et al. What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis. Lipids Health Dis. 2017;16(1):111. https:\/\/doi.org\/10.1186\/s12944-017-0506-6.","journal-title":"Lipids Health Dis"},{"issue":"5","key":"2041_CR33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","volume":"48","author":"M Ruscica","year":"2016","unstructured":"Ruscica M, Ferri N, Macchi C, et al. Liver fat accumulation is associated with circulating PCSK9. Ann Med. 2016;48(5):384\u201391. https:\/\/doi.org\/10.1080\/07853890.2016.1188328.","journal-title":"Ann Med"},{"issue":"31","key":"2041_CR34","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.2174\/1381612824666181010123127","volume":"24","author":"E Theocharidou","year":"2018","unstructured":"Theocharidou E, Papademetriou M, Reklou A, Sachinidis A, Boutari C, Giouleme O. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors. Curr Pharm Des. 2018;24(31):3654\u20137. https:\/\/doi.org\/10.2174\/1381612824666181010123127.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2041_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1743-7075-10-4","volume":"10","author":"B Cariou","year":"2013","unstructured":"Cariou B, Langhi C, Le Bras M, et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab (London). 2013;10(1):4. https:\/\/doi.org\/10.1186\/1743-7075-10-4.","journal-title":"Nutr Metab (London)"},{"issue":"3","key":"2041_CR36","doi-asserted-by":"publisher","first-page":"E335","DOI":"10.1111\/hepr.12920","volume":"48","author":"H Miyaaki","year":"2018","unstructured":"Miyaaki H, Miuma S, Taura N, et al. PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C. Hepatol Res. 2018;48(3):E335\u20139. https:\/\/doi.org\/10.1111\/hepr.12920.","journal-title":"Hepatol Res"},{"issue":"4","key":"2041_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/lt.22004","volume":"16","author":"K Yalamanchili","year":"2010","unstructured":"Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or non-alcoholic fatty liver disease. Liver Transpl. 2010;16(4):431\u20139.","journal-title":"Liver Transpl"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02041-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-02041-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02041-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T11:28:18Z","timestamp":1638876498000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-02041-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2041"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-02041-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board of Shiraz Transplant Center, Abu-Ali Sina hospital. Written informed consents were obtained from each patient after explaining the study protocol including harms and benefits of the study during blood sampling and performing transient elastography. The study protocol was performed in accordance with the Helsinki Declaration as revised in Seoul 2008.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"458"}}